Sarah Lowndes - Publications

Affiliations: 
2003-2006 University of Oxford, Oxford, United Kingdom 

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2009 Lowndes SA, Sheldon HV, Cai S, Taylor JM, Harris AL. Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvascular Research. 77: 314-26. PMID 19323979 DOI: 10.1016/j.mvr.2009.01.003  0.41
2008 Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7526-34. PMID 19010871 DOI: 10.1158/1078-0432.CCR-08-0315  0.402
2006 Lowndes SA, Harris AL. The role of copper in tumour angiogenesis. Journal of Mammary Gland Biology and Neoplasia. 10: 299-310. PMID 16924372 DOI: 10.1007/s10911-006-9003-7  0.442
2006 Lowndes SA, Adams A, Timms A, Middleton M, Hayward C, Reich SD, Mazar AP, Harris AL. Phase I study of ATN-224 in patients (pts) with advanced solid tumours Journal of Clinical Oncology. 24: 2065-2065. DOI: 10.1200/jco.2006.24.18_suppl.2065  0.387
2006 Doñate F, Lowndes S, Juarez J, Manuia M, Smith E, Liu N, Hayward C, Batuman O, Harris A, Mazar A. 132 POSTER Translation of in vitro markers of the anti-angiogenic and anti-tumor activity of the SOD1 inhibitor ATN-224 to clinical trials European Journal of Cancer Supplements. 4: 43. DOI: 10.1016/s1359-6349(06)70138-0  0.302
2004 Lowndes SA, Harris AL. Copper chelation as an antiangiogenic therapy Oncology Research. 14: 529-539. PMID 15666995 DOI: 10.3727/0965040042707952  0.443
Show low-probability matches.